Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Core Points - Biodexa Pharmaceuticals PLC has received allowance for a U.S. patent covering its oral rapamycin nanoparticle preparations, known as eRapa, which is set to issue on March 4, 2025, and is expected to expire in March 2034 [1] - The company plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) in the next quarter, with substantial funding from a $17 million grant from the Cancer Prevention Research Institute of Texas (CPRIT) [2] - eRapa is a proprietary oral formulation of rapamycin, an mTOR inhibitor, designed to improve bioavailability and reduce toxicity associated with existing rapamycin formulations [2][5] Company Overview - Biodexa is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs, with lead programs including eRapa for FAP and non-muscle invasive bladder cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare brain cancers [4][8] - The company is headquartered in Cardiff, UK, and utilizes proprietary drug delivery technologies to enhance the bio-distribution of its medicines [8] Funding and Research Impact - CPRIT has awarded$2.9 billion in grants to Texas research institutions, supporting significant advancements in cancer research and prevention, which includes funding for Biodexa's Phase 3 study [3] - The funding from CPRIT has generated over $5.7 billion in additional public and private investment, highlighting the importance of such grants in advancing scientific knowledge and clinical applications [3]